# Kabeer Aziz

> Kabeer Aziz is a Series C investor at Global Health Investment Fund (GHIF) backing Biotechnology. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Global Health Investment Fund (GHIF)](https://shizune.co/investors/profile/the-global-health-investment-fund-ghif)
- Location: New York, United States
- Total investments: 6
- Last investment: Oct 2023
- Lead investor: 17%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/kaziz107

Kabeer Aziz is a Series C investor at Global Health Investment Fund (GHIF) in New York focused on Biotechnology and Medical. Kabeer Aziz - Associate @ Global Health Investment Fund (GHIF)

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| Medical | 2 | 33% |
| Health Care | 2 | 33% |
| Wellness | 1 | 17% |
| Biopharma | 1 | 17% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 33% |
| Series A | 1 | 17% |
| Series B | 1 | 17% |
| Funding Round | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 1 | 17% |
| Switzerland | 1 | 17% |
| United Kingdom | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $57.4M |  | Oct 11, 2023 |  |
| LimmaTech Biologics | LimmaTech Biologics AG is a clinical-stage biopharmaceutical company. | $36.5M | Series A | Oct 09, 2023 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $23.4M | Series C | Dec 15, 2022 |  |
| Pulmocide | Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract. | $52M | Series C | Dec 06, 2022 |  |
| Pulmocide | Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract. | $92M | Series C | May 27, 2021 |  |
| Minervax | Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains. | $52M | Series B | Dec 15, 2020 |  |

6 of 6 investments shown.

## Co-investors
- [Industrifonden](https://shizune.co/investors/profile/industrifonden) — VC Fund, 3 deals together
- [Jeito Capital](https://shizune.co/investors/profile/jeito-capital) — VC Fund, 3 deals together
- [Repair Impact Fund](https://shizune.co/investors/profile/repair-impact-fund) — VC Fund, 3 deals together
- [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures) — VC Fund, 3 deals together
- [Sunstone Life Science Ventures](https://shizune.co/investors/profile/sunstone-capital-life-science) — VC Fund, 3 deals together
- [Wellington Partners](https://shizune.co/investors/profile/wellington-partners) — VC Fund, 3 deals together

## About Global Health Investment Fund (GHIF)

VC Fund · New York, United States

The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.

2 contacts available at Global Health Investment Fund (GHIF).

| Name | Title | Profile |
| --- | --- | --- |
| Curt LaBelle | Managing Partner & President | https://shizune.co/investors/profile/curt-labelle |
| Kabeer Aziz | Associate | https://shizune.co/investors/profile/kabeer-aziz |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Kabeer Aziz invest in?

Kabeer Aziz invests primarily in Biotechnology, Medical and Health Care startups, most often at Series C and Series A stage. Most of the 6 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Kabeer Aziz last invest?

The most recent investment recorded for Kabeer Aziz closed in Oct 2023. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co